Equine digital tendons show breed‐specific differences in their mechanical properties that may relate to athletic ability and predisposition to injury

Background Throughout the ages, human subjects have selected horse breeds for their locomotor capacities. Concurrently, tissue properties may have diversified because of specific requirements of different disciplines. Objectives The aim of this study was to compare the biomechanical properties of tendons with different functions between equine breeds traditionally selected for racing or sport. Study design This study used ex vivo tendons and compared the mechanical properties of the common digital extensor tendon (CDET) and superficial digital flexor tendon (SDFT) between racehorses (Thoroughbred [TB]) and sports horses (Friesian Horse [FH], Warmblood [WB]). Methods The SDFT and CDET of FH (n = 12), WBs (n = 12) and TBs (n = 8) aged 3-12 years were harvested. The cross sectional area (cm(2)), maximal load (N), ultimate strain (%), ultimate stress (MPa) and elastic modulus (MPa) were determined and tested for significant differences between the breeds (P<0.05). Results The SDFT from WB horses had a significantly lower elastic modulus than TB horses and failed at a higher strain and load than both FHs and TBs. The mechanical properties of the CDET did not differ between breeds. In agreement with previous studies, the CDET failed at a higher stress and had a higher elastic modulus than the SDFT and, for the WB group of horses only, failed at a significantly lower strain. Interestingly, the mode of failure differed between breeds, particularly with respect to the FHs. Main limitations The exercise history of horses used in this study was unknown and the age-range was relatively large; both these factors may have influenced the absolute properties reported in this study. Conclusions This study shows for the first time that mechanical properties of the SDFT differ between breeds. These properties are likely to be related to selection for high-speed vs. an extravagant elastic gait and may be an important indicator of performance ability. The is available in Spanish - see Supporting Informatio

Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis

Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC) are rare, inherited cholestatic liver disorders that manifest in infants and children and are associated with impaired bile flow (ie cholestasis), pruritus and potentially fatal liver disease. There are no effective or approved pharmacologic treatments for these diseases (standard medical treatments are supportive only), and new, noninvasive options would be valuable. Typically, bile acids undergo biliary secretion and intestinal reabsorption (ie enterohepatic circulation). However, in these diseases, disrupted secretion of bile acids leads to their accumulation in the liver, which is thought to underlie pruritus and liver-damaging inflammation. One approach to reducing pathologic bile acid accumulation in the body is surgical biliary diversion, which interrupts the enterohepatic circulation (eg by diverting bile acids to an external stoma). These procedures can normalize serum bile acids, reduce pruritus and liver injury and improve quality of life. A novel, nonsurgical approach to interrupting the enterohepatic circulation is inhibition of the ileal bile acid transporter (IBAT), a key molecule in the enterohepatic circulation that reabsorbs bile acids from the intestine. IBAT inhibition has been shown to reduce serum bile acids and pruritus in trials of paediatric cholestatic liver diseases. This review explores the rationale of inhibition of the IBAT as a therapeutic target, describes IBAT inhibitors in development and summarizes the current data on interrupting the enterohepatic circulation as treatment for cholestatic liver diseases including ALGS and PFIC

Goat Milk Based Infant Formula in Newborns:A Double-Blind Randomized Controlled Trial on Growth and Safety.

Objectives: We aimed to determine the growth and safety parameters in newborns fed a goat milk based infant formula (GMF) using a randomized double-blind trial, in which a cow milk formula (CMF) served as a control and a breast fed (BF) group as a reference. Methods: Healthy term infants (n = 218) aged up to 14 days were recruited from 25 European study centers and randomized to GMF or CMF. Weight, length, head circumference were measured at baseline, and at 14, 28, 56, 84, and 112 days at the study clinics. Adverse events were recorded and stool characteristics, reflux, fussiness, colic, and flatulence were self-reported by parents in 3-day diaries. Anthropometric measurements were transformed to WHO standardized age- and sex-adjusted z-scores. Analyses of covariance and linear mixed modeling were used to statistically analyze growth, while adjusting for potential confounders when studying the breast-fed group (n = 86). Results: Comparing the GMF to the CMF group, weight gain [mean difference 227.8 g (95% CI -16.6 to -439.0)] and z-scores for anthropometric measurements were similar after 112 days intervention. Infant formula groups showed greater mean (SD) weight z-scores than the BF group from 84 days onwards (GMF: 0.28 (0.84), CMF: 0.12 (0.88), BF -0.19 (1.02), P < 0.05), whereas length and head circumference z-scores were similar. Incidences of serious adverse events and reflux, fussiness, colic, and flatulence were similar among the three groups. Conclusion: Our data demonstrate that GMF provides adequate growth, has a good tolerability, and is safe to use in infants